摘要
目的:探讨文拉法辛缓释剂对伴有高血压的老年期抑郁症的疗效和安全性。方法:使用文拉法辛缓释剂对30例伴有高血压的老年期抑郁症和30例无高血压的老年期抑郁症患者进行为期6周的对照治疗,在治疗前及治疗后第1、2、4、6周末评定汉密尔顿抑郁量表(HAMD 17项),并进行临床疗效评定, 监测血压,记录不良反应。结果:高血压组和非高血压组患者的HAMD评分均从第1周末起明显下降(P< 0．05或P<0．01),且一直持续至治疗第6周末。两组6周末的有效率和临床治愈率差异无显著性(P> 0．05)。高血压组患者使用文拉法辛缓释剂治疗后第2周末收缩压变化值显著高于非高血压患者(0．9±0．4, 0．6±0．5,P=0．01)。两组间的不良反应发生率差异无统计学意义(P>0．05)。结论:文拉法辛缓释剂治疗老年期抑郁症疗效肯定,不良反应少,对血压无明显影响。
Objective： To assess the efficacy and safety of venlafaxine XR in aged patients with major depressive disorder and hypertension. Methods： All subjects met the CCMD-3 criteria for major depressive disorder. 30 subjects had hypertension and 30 subjects had not. All subjects were treated with venlafaxine XR for 6 weeks. The efficacy was measured with HAMD, while the side effects were recorded. Results： In both group, the HAMD total scores were significantly decreased over time since week 1. After 6 weeks of treatment,the response rates and remission rates of two groups were similar. The between-group difference of change of systolic pressure at week 2 from baseline was statistically significant （0. 9±0. 4,0.6 ± 0. 5, P = 0. 01 ）. There were no significant differences in adverse effects between two groups （ P 〉 0. 05 ）. Condusion： Venlafaxine XR is effective and safe in the treatment of elderly depression.
出处
《中国心理卫生杂志》
CSSCI
CSCD
北大核心
2006年第5期339-341,共3页
Chinese Mental Health Journal
